en افزودن پروژسترون عضلانی به واژینال برای حمایت از فاز لوتئال در چرخه های انتقال جنین تازه: یک مطالعه مقطعی Assisted Reproductive Technologies Original Article Original Article <div style="text-align: justify;"><span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مقدمه: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نقص فاز لوتئال در فناوری کمک&shy;باروری (</span></span><span dir="LTR" style="font-size:10.0pt">ART</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">) رایج است و با تولید ناکافی پروژسترون مشخص می</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">شود. مطالعات مختلف نشان داده</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">اند که تجویز پروژسترون در چرخه</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">های انتقال جنین تازه، میزان حاملگی بالینی و میزان تولد زنده را افزایش می</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">دهد. تجویز پروژسترون انواع مختلفی دارد مانند: خوراکی، واژینال، عضلانی و زیرجلدی.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">هدف: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">هدف از این مطالعه مقایسه اثر افزودن پروژسترون عضلانی به پروژسترون واژینال برای حمایت از فاز لوتئال در چرخه انتقال جنین تازه انجام شد.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">مواد و روش&shy; ها: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">این مطالعه اطلاعات مربوط به 355 زن که در فاصله مارس 2020 تا فوریه 2021، انتقال جنین تازه را در مرکز تحقیقات ناباروری یزد انجام داده بودند را بررسی کرد. جمعیت شرکت&shy;کنندگان بر اساس نوع رژیم حمایت فاز لوتئال مورد استفاده به دو گروه تقسیم شدند گروه اول (تعداد = 173): 400 میلی&shy;گرم پروژسترون واژینال به تنهایی دو بار در روز از روز برداشت تخمک دریافت کردند. و گروه دوم (تعداد = 182): 50 میلی&shy;گرم پروژسترون </span></span><span dir="LTR" style="font-size:10.0pt">IM</span> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">به اضافه پروژسترون واژینال 400 میلی</span></span><span dir="LTR" style="font-size:11.0pt"><span arial="" style="font-family:">&shy;</span></span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">گرم، دو بار در روز از روز برداشت تخمک دریافت کردند. میزان حاملگی شیمیایی و بالینی بین دو گروه مقایسه شد.</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتایج: </span></span></b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">ویژگی‌های اساسی دو گروه از نظر آماری مشابه بود. میزان حاملگی شیمیایی و بالینی در گروه پروژسترون واژینال به همراه پروژسترون در مقایسه با گروه پروژسترون واژینال بیشتر بود. همچنین حاملگی شیمیایی بین دو گروه تفاوت معنی&shy;داری نشان داد (011/0 </span></span><span lang="FA" style="font-size:10.0pt">= </span><span dir="LTR" style="font-size:10.0pt">p</span><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">).</span></span></span></span></span></span></span><br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">نتیجه &shy;گیری:</span></span></b> <span lang="FA" style="font-size:11.0pt"><span b="" mitra="" style="font-family:">یافته‌ها نشان داد که افزودن پروژسترون عضلانی به پروژسترون واژینال باعث بهبود میزان شیمیایی در انتقال جنین تازه می‌شود.</span></span></span></span></span></span></span><br> <br> <span style="font-size:12pt"><span style="text-justify:inter-ideograph"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><i><span lang="FA" style="font-size:10.0pt"><span b="" mitra="" style="font-family:">کلمات کلیدی:</span></span></i></b><span lang="FA" style="font-size:10.0pt"><span b="" mitra="" style="font-family:"> <i>فاز لوتئال، پروژسترون، فناوری کمک&shy;باروری، انتقال جنین.</i></span></span></span></span></span></span></span></div> <div style="text-align: justify;"><a name="_Hlk93494171"></a><span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Background:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> Luteal phase deficiency is common in assisted reproductive technology and is characterized by inadequate progesterone production. Various studies have shown that administration of progesterone in fresh embryo transfer cycles increases the rate of clinical pregnancy and live birth rate. Progesterone administration has variable types: oral, vaginal, oil-based intramuscular, and subcutaneous. </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><a name="_Hlk93494171"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Objective:</span></span></b></a><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> This study aims to compare the effect of adding intramuscular progesterone to the vaginal progesterone for luteal phase support in the fresh embryo transfer cycle.<a name="_Hlk92220948"></a></span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Materials and Methods:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> This study reviewed the information related to 355 women who had a fresh embryo transfer between March 2020 and February 2021 at the Yazd Reproductive Sciences Institute, Yazd, Iran. </span></span><a name="_Hlk92224363"></a><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">The participants population were divided into 2 groups based on the type of luteal phase support regime: group I (n = 173) received <a name="_Hlk92637623">400 mg </a>vaginal progesterone alone <a name="_Hlk92637611">twice a day </a><a name="_Hlk92807138">from the day of ovum pick up</a>; and group II (n = 182) received 50 mg IM of progesterone in addition to vaginal </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">progesterone 400 mg twice a day from the day of ovum pick up. Chemical and clinical pregnancy rates were compared between groups.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><a name="_Hlk92309343"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Results:</span></span></b></a><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> The </span></span><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">basic characteristics of groups were statistically similar. The rates of chemical and clinical pregnancy were higher in the vaginal plus IM progesterone group than in the vaginal progesterone group. Moreover, <a name="_Hlk92630876">chemical pregnancy </a>showed a significant difference between the groups (p = 0.011). </span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Conclusion:</span></span></b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""> Our findings demonstrated that the addition of IM progesterone to the vaginal progesterone improves the <a name="_Hlk92630950">chemical pregnancy rate </a>in fresh embryo transfer.</span></span></span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><i><span style="font-size:10.0pt"><span style="font-family:"Times New Roman","serif""></span></span></i></span></span></span></div> فاز لوتئال, پروژسترون, فناوری کمک­باروری, انتقال جنین. Luteal phase, Progesterone, Assisted reproductive technology, Embryo transfer. 745 752 http://ijrm.ir/browse.php?a_code=A-10-226-7&slc_lang=en&sid=1 Samaneh Jalaliani samane.jalaliani@gmail.com 0000-0003-4718-1200 Yes Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Robab Davar r_davar@yahoo.com 0000-0002-5296-5707 No Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Farzad Akbarzadeh Akbarzzadehf@mums.ac.ir 0000-0002-5976-123X No Department of Psychiatry, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Fatemeh Emami fatemehemami@gmail.com 0000-0002-9792-5338 No Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Maryam Eftekhar eftekharmaryam@yahoo.com 0000-0003-3835-5635 No Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.